If insomnia persists beyond 8 weeks or significantly impacts daytime function, dose reduction or switching to a different GLP-1 agent (such as semaglutide) may be necessary
The intestinal hormone glucagon-like peptide 1 (GLP-1) is potentially associated with IBS pathophysiology
However, you should know that it is serious medicine that should only be used when absolutely necessary
Metabolic indicators that may correlate with reduced GLP-1 activity include: Persistent hyperglycemia despite dietary modifications, particularly elevated postprandial (after-meal) blood glucose levels Difficulty achieving satiety after meals, leading to continued hunger and frequent snacking Progressive weight gain that is resistant to conventional dietary interventions Diagnosis of prediabetes or type 2 diabetes , conditions associated with impaired incretin response Metabolic syndrome features , including central obesity, hypertension, and dyslipidemia It is important to emphasize that these signs are not diagnostic of GLP-1 imbalance specifically, as they can result from numerous metabolic, endocrine, or lifestyle factors
Delving into the specifics with a focus on B12 Aventura, unraveling unique aspects and potential alternatives in B12 supplementation